Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese

被引：4

作者：

Luo, CH ^{[1
]}

Wang, A ^{[1
]}

Zhu, RH ^{[1
]}

Zhang, WX ^{[1
]}

Mo, W ^{[1
]}

Yu, BN ^{[1
]}

Chen, GL ^{[1
]}

Ou-Yang, DS ^{[1
]}

Duan, XH ^{[1
]}

Abd El-Aty, AM ^{[1
]}

Zhou, HH ^{[1
]}

机构：

[1] Cent S Univ, Inst Clin Pharmacol, Pharmacogenet Res Inst, Changsha 410078, Hunan, Peoples R China

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 60卷 / 06期

关键词：

CYP2C9; gender; hyperlipidaemia;

D O I：

10.1111/j.1365-2125.2005.02498.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aims To investigate the association of CYP2C9*3 and *6 with hyperlipidaemia in Chinese. Methods Four hundred and seventy-six Chinese participated in the study, including 211 uncomplicated hyperlipidaemic patients and 265 healthy controls. PCR-RFLP was used to identify CYP2C9*3 and *6. Results CYP2C9*6 was not detected in this study. The allelic frequency of CYP2C9*3 was 0.039 (95% CI 0.022, 0.056). A nonsignificant difference existed in CYP2C9*3 frequencies between males and females (P = 0.605, OR = 1.194, 95% CI 0.610, 2.336), patients and controls (P = 0.063, OR = 0.506, 95% CI 0.244, 1.049) in the total population. However, in the female group, CYP2C9*3 frequency in patients with hyperlipidaemia was significantly lower than that in controls (P < 0.0001, OR = 0.062, 95% CI 0.008, 0.476). Conclusions The association of CYP2C9*3 with hyperlipidaemia was specific for females in this Chinese population.

引用

页码：629 / 631

页数：3

共 12 条

[1]

Cheng ZN, 2001, ACTA PHARMACOL SIN, V22, P148

[2] Management of hypercholesterolaemia in postmenopausal women [J].

Davidson, MH ;

Maki, KC ;

Karp, SK ;

Ingram, KA .

DRUGS & AGING, 2002, 19 (03) :169-178

[3]

Goldstein JA, 2002, DRUG METAB REV, V34, P5

[4] Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men [J].

Jockenhövel, F ;

Bullmann, C ;

Schubert, M ;

Vogel, E ;

Reinhardt, W ;

Reinwein, D ;

Müller-Wieland, D ;

Krone, W .

METABOLISM-CLINICAL AND EXPERIMENTAL, 1999, 48 (05) :590-596

[5] Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin [J].

Kidd, RS ;

Curry, TB ;

Gallagher, S ;

Edeki, T ;

Blaisdell, J ;

Goldstein, JA .

PHARMACOGENETICS, 2001, 11 (09) :803-808

[6] Association study of the 5-HT2A receptor gene polymorphism, T102C and essential hypertension [J].

Liolitsa, D ;

Powell, JF ;

Prince, M ;

Lovestone, S .

JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (05) :335-339

[7] Genetic analysis of CYP2C9 polymorphism in a Japanese population [J].

Nasu, K ;

Kubota, T ;

Ishizaki, T .

PHARMACOGENETICS, 1997, 7 (05) :405-409

[8] Lipids and lipoproteins in women [J].

OBrien, T ;

Nguyen, TT .

MAYO CLINIC PROCEEDINGS, 1997, 72 (03) :235-244

[9] Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas [J].

Soucek, P ;

Sarmanová, J ;

Kristensen, VN ;

Apltauerová, M ;

Gut, I .

INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 2002, 75 (Suppl 1) :S86-S92

[10]

Xie H, 2002, CLIN PHARMACOL THER, V71, pP102

← 1 2 →